Current concepts in the biochemical assessment of the patient with acromegaly

Growth Hormone and IGF Research

Volumn 13, Issue 4, 2003, Pages 171-184

  Freda, Pamela U ^a  

^a Columbia Univ Coll of Phys/Surg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOPROTEIN; GROWTH HORMONE; PROTIRELIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGE; AGED; BIOCHEMISTRY; CHEMOLUMINESCENCE; DATA BASE; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; FLUOROMETRY; HEALTH STATUS; HORMONE DETERMINATION; HORMONE INHIBITION; HUMAN; HYPOPHYSIS FUNCTION; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; ORAL GLUCOSE TOLERANCE TEST; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTIRELIN TEST; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME;

EID: 0043074807     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00029-7     Document Type: Review

References (126)

1. D.R. Clemmons, L.E. Underwood, Nutritional regulation of IGF-I and IGF binding proteins, Annu. Rev. Nutr. 11 (1991) 393-412.
2. J.P. Thissen, J.M. Ketelslegers, L.E. Underwood, Nutritional regulation of the insulin-like growth factors, Endocr. Rev. 15 (1994) 80-101.
3. J.I. Jones, D.R. Clemmons, Insulin-like growth factors and their binding proteins: biological actions, Endocr. Rev. 16 (1995) 3-34.
4. J. Frystyk, P. Ivarsen, R.K. Stoving, R. Dall, T. Bek, C. Hagen, H. Orskov, Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay, Growth Horm. IGF Res. 11 (2001) 117-127.
5. D.R. Clemmons, J.J. Van Wyk, Factors controlling blood concentration of somatomedin C, Clin. Endocrinol. Metab. 13 (1984) 113-143.
6. M.L. Hartman, J.D. Veldhuis, M.L. Vance, A.C. Faria, R.W. Furlanetto, M.O. Thorner, Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy, J. Clin. Endocrinol. Metab. 70 (1990) 1375-1384.
7. S.W. Lamberts, P. Uitterlinden, P.C. Schuijff, J.G. Klijn, Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure', Clin. Endocrinol. (Oxf.) 29 (1988) 411-420.
8. A.J. van der Lely, W.W. de Herder, J.A. Janssen, S.W. Lamberts, Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis, J. Endocrinol. 155 (Suppl. 1) (1997) S9-S13, discussion S15-6.
9. K.Y. Ho, A.J. Weissberger, Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy, Clin. Endocrinol. (Oxf.) 41 (1994) 75-83.
10. G. Oppizzi, M.M. Petroncini, D. Dallabonzana, R. Cozzi, G. Verde, P.G. Chiodini, A. Liuzzi, Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation, J. Clin. Endocrinol. Metab. 63 (1986) 1348-1353.
11. A.L. Barkan, I.Z. Beitins, R.P. Kelch, Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion, J. Clin. Endocrinol. Metab. 67 (1988) 69-73.
12. J.M. Holly, A.M. Cotterill, R.C. Jemmott, D. Shears, S. al-Othman, T. Chard, J.A. Wass, Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-I (IGFBP-1) and sex hormone-binding globulin in acromegaly, Clin. Endocrinol. (Oxf.) 34 (1991) 275-280.
13. M. Rieu, F. Girard, H. Bricaire, M. Binoux, The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly, J. Clin. Endocrinol. Metab. 55 (1982) 147-153.
14. R.D. Dobrashian, D.J. O'Halloran, A. Hunt, C.G. Beardwell, S.M. Shalet, Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly, Clin. Endocrinol. (Oxf.) 38 (1993) 589-593.
15. P.U. Freda, R.E. Landman, R.E. Sundeen, K.D. Post, Gender and age in the biochemical assessment of cure of acromegaly, Pituitary 4 (2001) 163-171.
16. A.S. Bates, A.J. Evans, P. Jones, R.N. Clayton, Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion, Clin. Endocrinol. (Oxf.) 42 (1995) 417-423.
17. W.W. de Herder, A.J. van der Lely, J.A. Janssen, P. Uitterlinden, L.J. Holland, S.W. Lamberts, IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly, Clin. Endocrinol. (Oxf.) 43 (1995) 501-505.
18. H.J. Kim, S.H. Kwon, S.W. Kim, D.J. Park, C.S. Shin, K.S. Park, S.Y. Kim, B.Y. Cho, H.K. Lee, Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults, Horm. Res. 56 (2001) 117-123.
19. F. Roelfsema, M. Frolich, H. Van Dulken, Somatomedin-C levels in treated and untreated patients with acromegaly, Clin. Endocrinol. (Oxf.) 26 (1987) 137-144.
20. D.R. Clemmons, J.J. Van Wyk, E.C. Ridgway, B. Kliman, R.N. Kjellberg, L.E. Underwood, Evaluation of acromegaly by radioimmunoassay of somatomedin-C, N. Engl. J. Med. 301 (1979) 1138-1142.
21. J. Lindholm, B. Giwercman, A. Giwercman, J. Astrup, P. Bjerre, N.E. Skakkebaek, Investigation of the criteria for assessing the outcome of treatment in acromegaly, Clin. Endocrinol. (Oxf.) 27 (1987) 553-562.
22. G. Knappe, V. Hesse, G. Jahreis, W. Rohde, H. Gerl, Somatomedin-C in active and successfully treated acromegaly, Exp. Clin. Endocrinol. 91 (1988) 2-6.
23. S.J. Brockmeier, M. Buchfelder, E.F. Adams, W. Schott, R. Fahlbusch, Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery, Horm. Metab. Res. 24 (1992) 392-400.
24. P.U. Freda, K.D. Post, J.S. Powell, S.L. Wardlaw, Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly, J. Clin. Endocrinol. Metab. 83 (1998) 3808-3816.
25. E.V. Dimaraki, C.A. Jaffe, R. DeMott-Friberg, W.F. Chandler, A.L. Barkan, Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up, J. Clin. Endocrinol. Metab. 87 (2002) 3537-3542.
26. P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant [see comments], N. Engl. J. Med. 342 (2000) 1171-1177.
27. A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, Lancet 358 (2001) 1754-1759.
28. A. Barreca, E. Ciccarelli, F. Minuto, P. Bruzzi, G. Giordano, F. Camanni, Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly, Acta Endocrinol. (Copenh.) 120 (1989) 629-635.
29. L.D. Stonesifer, R.M. Jordan, P.O. Kohler, Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response, J. Clin. Endocrinol. Metab. 53 (1981) 931-934.
30. A.C. Moses, M.E. Molitch, C.T. Sawin, I.M. Jackson, B.J. Biller, R. Furlanetto, S. Reichlin, Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C, J. Clin. Endocrinol. Metab. 53 (1981) 752-758.
31. J.W. Nortier, R.J. Croughs, J.H. Thijssen, F. Schwarz, Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity, Clin. Endocrinol. (Oxf.) 22 (1985) 209-217.
32. J.A. Wass, D.R. Clemmons, L.E. Underwood, I. Barrow, G.M. Besser, J.J. Van Wyk, Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly, Clin. Endocrinol. (Oxf.) 17 (1982) 369-377.
33. H. Jasper, P. Pennisi, M. Vitale, A. Mella, G. Ropelato, A. Chervin, Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score, J. Endocrinol. Invest. 22 (1999) 29-34.
34. C. Paramo, O.M.A. Andrade, E. Fluiters, R. Luna, J. de la Fuente, R.V. Garcia-Mayor, Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly, Metabolism 46 (1997) 494-498.
35. B.M. Arafah, J.L. Rosenzweig, R. Fenstermaker, R. Salazar, C.E. McBride, W. Selman, Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly, J. Lab. Clin. Med. 109 (1987) 346-354.
36. A. Colao, P. Marzullo, D. Ferone, L. Spinelli, A. Cuocolo, D. Bonaduce, M. Salvatore, V. Boerlin, I. Lancranjan, G. Lombardi, Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly, J. Clin. Endocrinol. Metab. 85 (2000) 3132-3140.
37. A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A.M. Della Morte, R. Pivonello, M. Salvatore, G. Lombardi, Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance, J. Clin. Endocrinol. Metab. 86 (2001) 1551-1557.
38. B. Swearingen, F.G. Barker 2nd, L. Katznelson, B.M. Biller, S. Grinspoon, A. Klibanski, N. Moayeri, P.M. Black, N.T. Zervas, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly [see comments], J. Clin. Endocrinol. Metab. 83 (1998) 3419-3426.
39. C. Beauregard, U. Truong, J. Hardy, O. Serri, Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly, Clin. Endocrinol. (Oxf.) 58 (2003) 86-91.
40. D. LeRoith, D. Clemmons, P. Nissley, M.M. Rechler, NIH conference. Insulin-like growth factors in health and disease [see comments], Ann. Intern. Med. 116 (1992) 854-862.
41. T.J. Merimee, J. Zapf, E.R. Froesch, Insulin-like growth factors in the fed and fasted states, J. Clin. Endocrinol. Metab. 55 (1982) 999-1002.
42. K. Hall, A. Hilding, M. Thoren, Determinants of circulating insulin-like growth factor-I, J. Endocrinol. Invest. 22 (1999) 48-57.
43. W.J. Smith, L.E. Underwood, D.R. Clemmons, Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults, J. Clin. Endocrinol. Metab. 80 (1995) 443-449.
44. R. Gama, M. Labib, J.D. Teale, V. Marks, Acromegaly with a misleading normal plasma insulin-like growth factor 1. Ann. Clin. Biochem. 26 (Pt 1) (1989) 102-103.
45. C.J. Strasburger, M. Bidlingmaier, Z. Wu, K.M. Morrison, Normal values of insulin-like growth factor I and their clinical utility in adults, Horm. Res. 55 (Suppl. 2) (2001) 100-105.
46. A. Hilding, K. Hall, I.L. Wivall-Helleryd, M. Saaf, A.L. Melin, M. Thoren, Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects, J. Clin. Endocrinol. Metab. 84 (1999) 2013-2019.
47. K. Landin-Wilhelmsen, L. Wilhelmsen, G. Lappas, T. Rosen, G. Lindstedt, P.A. Lundberg, B.A. Bengtsson, Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin, Clin. Endocrinol. (Oxf.) 41 (1994) 351-357.
48. E. Ghigo, G. Aimaretti, L. Gianotti, J. Bellone, E. Arvat, F. Camanni, New approach to the diagnosis of growth hormone deficiency in adults, Eur. J. Endocrinol. 134 (1996) 352-356.
49. D. Evain-Brion, P. Garnier, R.M. Schimpff, J.L. Chaussain, J.C. Job, Growth hormone response to thyrotropin-releasing hormone and oral glucose-loading tests in tall children and adolescents, J. Clin. Endocrinol. Metab. 56 (1983) 429-432.
50. G. van den Berg, J.D. Veldhuis, M. Frolich, F. Roelfsema, An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women, J. Clin. Endocrinol. Metab. 81 (1996) 2460-2467.
51. R. Dall, S. Longobardi, C. Ehrnborg, N. Keay, T. Rosen, J.O. Jorgensen, R.C. Cuneo, M.A. Boroujerdi, A. Cittadini, R. Napoli, J.S. Christiansen, B.A. Bengtsson, L. Sacca, R.C. Baxter, E.E. Basset, P.H. Sonksen, The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group, J. Clin. Endocrinol. Metab. 85 (2000) 4193-4200.
52. K.Y. Ho, W.S. Evans, R.M. Blizzard, J.D. Veldhuis, G.R. Merriam, E. Samojlik, R. Furlanetto, A.D. Rogol, D.L. Kaiser, M.O. Thorner, Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations, J. Clin. Endocrinol. Metab. 64 (1987) 51-58.
53. A.J. Weissberger, K.K. Ho, L. Lazarus, Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women, J. Clin. Endocrinol. Metab. 72 (1991) 374-381.
54. H.J. Cardim, C.M. Lopes, D. Giannella-Neto, A.M. da Fonseca, J.A. Pinotti, The insulin-like growth factor-I system and hormone replacement therapy, Fertil. Steril. 75 (2001) 282-287.
55. C. Parkinson, W.D. Ryder, P.J. Trainer, The relationship between serum GH and serum IGF-I in acromegaly is gender-specific, J. Clin. Endocrinol. Metab. 86 (2001) 5240-5244.
56. J.M. Gomez, F.J. Maravall, N. Gomez, M.A. Navarro, R. Casamitjana, J. Soler, Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected, Clin. Endocrinol. (Oxf.) 58 (2003) 213-219.
57. H. Vierhapper, G. Heinze, A. Gessl, M. Exner, C. Bieglmayr, Use of the oral glucose tolerance test to define remission in acromegaly, Metabolism 52 (2003) 181-185.
58. J.P. Miell, A.M. Taylor, M. Zini, H.G. Maheshwari, R.J. Ross, R. Valcavi, Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J. Clin. Endocrinol. Metab. 76 (1993) 950-955.
59. S. Feld, R. Hirschberg, Growth hormone, the insulin-like growth factor system, and the kidney. Endocr. Rev. 17 (1996) 423-480.
60. A.C. Goldberg, B. Trivedi, J.A. Delmez, H.R. Harter, W.H. Daughaday, Uremia reduces serum insulin-like growth factor I, increases insulin-like growth factor II, and modifies their serum protein binding, J. Clin. Endocrinol. Metab. 55 (1982) 1040-1045.
61. J. Frystyk, P. Ivarsen, C. Skjaerbaek, A. Flyvbjerg, E.B. Pedersen, H. Orskov, Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure, Kidney Int. 56 (1999) 2076-2084.
62. N.A. Wong, J.A. Ahlquist, C. Camacho-Hubner, C.J. Goodwin, M. Dattani, N.J. Marshall, J.A. Wass, Acromegaly or chronic renal failure: a diagnostic dilemma, Clin. Endocrinol. (Oxf.) 46 (1997) 221-226.
63. D.S. Schalch, M. Kalayoglu, J.D. Pirsch, H. Yang, M. Raslich, S. Rajpal, Serum insulin-like growth factors and their binding proteins in patients with hepatic failure and after liver transplantation, Metabolism 47 (1998) 200-206.
64. O.M. Herlihy, P. Perros, Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma, Diabetes Metab. Res. Rev. 16 (2000) 211-216.
65. D.R. Clemmons, Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency, Horm. Res. 55 (Suppl. 2) (2001) 73-79.
66. J.A. Janssen, S.W. Lamberts, Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis, J. Endocrinol. Invest. 22 (1999) 313-315.
67. P. Marzullo, C. Di Somma, K.L. Pratt, J. Khosravi, A. Diamandis, G. Lombardi, A. Colao, R.G. Rosenfeld, Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults, J. Clin. Endocrinol. Metab. 86 (2001) 3001-3008.
68. J. Frystyk, C. Skjaerbaek, B. Dinesen, H. Orskov, Free insulin-like growth factors (IGF-I and IGF-II) in human serum, FEBS Lett. 348 (1994) 185-191.
69. B. Stoffel-Wagner, W. Springer, F. Bidlingmaier, D. Klingmuller, A comparison of different methods for diagnosing acromegaly, Clin. Endocrinol. (Oxf.) 46 (1997) 531-537.
70. S.B. Sneppen, M. Lange, L.M. Pedersen, L.L.O. Kristensen, K.M. Main, A. Juul, N.E. Skakkebaek, U. Feldt-Rasmussen, Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly, Growth Horm. IGF Res. 11 (2001) 384-391.
71. E. Duncan, J.A. Wass, Investigation protocol: acromegaly and its investigation, Clin. Endocrinol. (Oxf.) 50 (1999) 285-293.
72. B.M. Chang-DeMoranville, I.M. Jackson, Diagnosis and endocrine testing in acromegaly, Endocrinol. Metab. Clin. North Am. 21 (1992) 649-668.
73. M.L. Hartman, J.D. Veldhuis, M.O. Thorner, Normal control of growth hormone secretion, Horm. Res. 40 (1993) 37-47.
74. V.J. Parfitt, D. Flanagan, P. Wood, B.A. Leatherdale, Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1, Clin. Endocrinol. (Oxf.) 49 (1998) 647-652.
75. A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. Von Werder, S. Melmed, Criteria for cure of acromegaly: a consensus statement, J. Clin. Endocrinol. Metab. 85 (2000) 526-529.
76. S.R. Peacey, S.M. Shalet, Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly, Ann. Clin. Biochem. 38 (2001) 297-303.
77. S. Melmed, I. Jackson, D. Kleinberg, A. Klibanski, Current treatment guidelines for acromegaly, J. Clin. Endocrinol. Metab. 83 (1998) 2646-2652.
78. C. Camacho-Hubner, Assessment of growth hormone status in acromegaly: What biochemical markers to measure and how?, Growth Horm. IGF Res. 10 (Suppl. B) (2000) S125-S129.
79. C.A. Jaffe, A.L. Barkan, Acromegaly. Recognition and treatment, Drugs 47 (1994) 425-445.
80. N. Hattori, A. Shimatsu, Y. Kato, H. Koshiyama, Y. Ishikawa, H. Assadian, T. Tanoh, M. Nagao, H. Imura, Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly, J. Clin. Endocrinol. Metab. 70 (1990) 771-776.
81. J.M. Earll, L.L. Sparks, P.H. Forsham, Glucose suppression of serum growth hormone in the diagnosis of acromegaly, JAMA 201 (1967) 628-630.
82. I.M. Chapman, M.L. Hartman, M. Straume, M.L. Johnson, J.D. Veldhuis, M.O. Thorner, Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women, J. Clin. Endocrinol. Metab. 78 (1994) 1312-1319.
83. P.M. Stewart, S. Smith, J. Seth, S.E. Stewart, D. Cole, C.R. Edwards, Normal growth hormone response to the 75g oral glucose tolerance test measured by immunoradiometric assay, Ann. Clin. Biochem. 26 (Pt 2) (1989) 205-206.
84. A.C. Costa, A. Rossi, C.E. Martinelli Jr., H.R. Machado, A.C. Moreira, Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: Should we achieve strict normal GH levels for a biochemical cure?, J. Clin. Endocrinol. Metab. 87 (2002) 3142-3147.
85. A.G. Frantz, M.T. Rabkin, Effects of estrogen and sex difference on secretion of human growth hormone, J. Clin. Endocrinol. Metab. 25 (1965) 1470-1480.
86. B.E. Engstrom, F.A. Karlsson, L. Wide, Gender differences in diurnal growth hormone and epinephrine values in young adults during ambulation, Clin. Chem. 45 (1999) 1235-1239.
87. B. Tonshoff, W.F. Blum, O. Mehls, Derangements of the somatotropic hormone axis in chronic renal failure, Kidney Int. Suppl. 58 (1997) S106-S113.
88. S.M. Pincus, E.F. Gevers, I.C. Robinson, G. van den Berg, F. Roelfsema, M.L. Hartman, J.D. Veldhuis, Females secrete growth hormone with more process irregularity than males in both humans and rats, Am. J. Physiol. 270 (1996) E107-E115.
89. Z. Zadik, S.A. Chalew, R.J. McCarter Jr., M. Meistas, A.A. Kowarski, The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals, J. Clin. Endocrinol. Metab. 60 (1985) 513-516.
90. L. De Marinis, A. Mancini, A. Bianchi, R. Gentilella, D. Valle, A. Giampietro, P. Zuppi, C. Anile, G. Maira, A. Giustina, Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients, Metabolism 51 (2002) 616-621.
91. A.C. Celniker, A.B. Chen, R.M. Wert Jr., B.M. Sherman, Variability in the quantitation of circulating growth hormone using commercial immunoassays, J. Clin. Endocrinol. Metab. 68 (1989) 469-476.
92. P.A. Levin, S.A. Chalew, L. Martin, A.A. Kowarski, Comparison of assays for growth hormone using monoclonal or polyclonal antibodies for diagnosis of growth disorders, J. Lab. Clin. Med. 109 (1987) 85-88.
93. E.O. Reiter, A.H. Morris, M.H. MacGillivray, D. Weber, Variable estimates of serum growth hormone concentrations by different radioassay systems, J. Clin. Endocrinol. Metab. 66 (1988) 68-71.
94. L. Ebdrup, S. Fisker, H.H. Sorensen, M.B. Ranke, H. Orskov, Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein, Horm. Res. 51 (Suppl. 1) (1999) 20-26.
95. J. Seth, A. Ellis, R. Al-Sadie, Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme, Horm. Res. 51 (Suppl. 1) (1999) 13-19.
96. A.F. Bristow, International standards for growth hormone, Horm. Res. 51 (Suppl. 1) (1999) 7-12.
97. M.B. Ranke, H. Orskov, A.F. Bristow, J. Seth, G. Baumann, Consensus on how to measure growth hormone in serum, Horm. Res. 51 (Suppl. 1) (1999) 27-29.
98. A. Vinik, B. Pimstone, B. Buchanan-Lee, Impairment of hyperglycemic induced growth hormone suppression in hyperthyroidism, J. Clin. Endocrinol. Metab. 28 (1968) 1534-1538.
99. M.D. Becker, G.C. Cook, A.D. Wright, Paradoxical elevation of growth hormone in active chronic hepatitis, Lancet 2 (1969) 1035-1039.
100. G.F. Pieters, A.G. Smals, P.W. Kloppenborg, Defective suppression of growth hormone after oral glucose loading in adolescence, J. Clin. Endocrinol. Metab. 51 (1980) 265-270.
101. R.W. Holl, P. Bucher, W. Sorgo, E. Heinze, J. Homoki, K.M. Debatin, Suppression of growth hormone by oral glucose in the evaluation of tall stature, Horm. Res. 51 (1999) 20-24.
102. A.S. Bates, W. Vanthoff, J.M. Jones, R.N. Clayton, Does treatment of acromegaly affect life expectancy, Metabolism-Clinical and Experimental 44 (1995) 1-5.
103. C. Rajasoorya, I.M. Holdaway, P. Wrightson, D.J. Scott, H.K. Ibbertson, Determinants of clinical outcome and survival in acromegaly, Clin. Endocrinol. (Oxf.) 41 (1994) 95-102.
104. S.M. Orme, R.J. McNally, R.A. Cartwright, P.E. Belchetz, Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group, J. Clin. Endocrinol. Metab. 83 (1998) 2730-2734.
105. P.J. Ho, C.A. Jaffe, R.D. Friberg, W.F. Chandler, A.L. Barkan, Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors, J. Clin. Endocrinol. Metab. 78 (1994) 1403-1410.
106. P.U. Freda, A.T. Nuruzzaman, K.D. Post, Significance of "abnormal" GH suppression after OGTT with normal IGF-I levels in postoperative patients with acromegaly, in: 84th Annual Meeting of the Endocrine Society, San Francisco, CA, June 19-22, 2002.
107. J.A. Wass, Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly, J. Endocrinol. 155 (Suppl. 1) (1997) S17-S19, discussion S21.
108. R. Sheaves, Interpretation of IGF-1 levels in the assessment of acromegaly. The Royal Society of Medicine. Current Medical Literature, Growth Hormone and Growth Factors 1 (1993) 59-61.
109. G.A. Kaltsas, A.M. Isidori, D. Florakis, P.J. Trainer, C. Camacho-Hubner, F. Afshar, I. Sabin, J.P. Jenkins, S.L. Chew, J.P. Monson, G.M. Besser, A.B. Grossman, Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity, J. Clin. Endocrinol. Metab. 86 (2001) 1645-1652.
110. S.R. Peacey, A.A. Toogood, J.D. Veldhuis, M.O. Thorner, S.M. Shalet, The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy, J. Clin. Endocrinol. Metab. 86 (2001) 259-266.
111. S. Grinspoon, D. Clemmons, B. Swearingen, A. Klibanski, Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly, J. Clin. Endocrinol. Metab. 80 (1995) 927-932.
112. W.F. Blum, M.B. Ranke, Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders, Horm. Res. 33 (Suppl. 4) (1990) 31-37.
113. R.C. Baxter, J.L. Martin, Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma, J. Clin. Invest. 78 (1986) 1504-1512.
114. A. Juul, K. Main, W.F. Blum, J. Lindholm, M.B. Ranke, N.E. Skakkebaek, The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients, Clin. Endocrinol. (Oxf.) 41 (1994) 85-93.
115. J.O. Jorgensen, N. Moller, J. Moller, J. Weeke, W.F. Blum, Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy, Metabolism 43 (1994) 579-583.
116. J.P. Thissen, J.M. Ketelslegers, D. Maiter, Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults, Growth Regul. 6 (1996) 222-229.
117. K.M. Morrison, Z. Wu, M. Bidlingmaier, C.J. Strasburger, Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly, Growth Horm. IGF Res. 11 (Suppl. A) (2001) S61-S63.
118. R.C. Baxter, The binding protein's binding protein - clinical applications of acid-labile subunit (ALS) measurement, J. Clin. Endocrinol. Metab. 82 (1997) 3941-3943.
119. R.C. Baxter, Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex, J. Clin. Endocrinol. Metab. 70 (1990) 1347-1353.
120. M. Arosio, S. Garrone, P. Bruzzi, G. Faglia, F. Minuto, A. Barreca, Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3, J. Clin. Endocrinol. Metab. 86 (2001) 1091-1098.
121. M.J. Khosravi, A. Diamandi, J. Mistry, R.G. Krishna, A. Khare, Acid-labile subunit of human insulin-like growth factor-binding protein complex: measurement, molecular, and clinical evaluation, J. Clin. Endocrinol. Metab. 82 (1997) 3944-3951.
122. I. Fukuda, N. Hizuka, E. Itoh, K. Yasumoto, Y. Ishikawa, Y. Murakami, A. Sata, K. Takano, Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3, Endocr. J. 49 (2002) 379-386.
123. N.R. Biermasz, J.W. Smit, H. van Dulken, F. Roelfsema, Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly, Clin. Endocrinol. (Oxf.) 56 (2002) 313-319.
124. S. Melmed, C. Ezrin, K. Kovacs, R.S. Goodman, L.A. Frohman, Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor, N. Engl. J. Med. 312 (1985) 9-17.
125. M.O. Thorner, R.L. Perryman, M.J. Cronin, A.D. Rogol, M. Draznin, A. Johanson, W. Vale, E. Horvath, K. Kovacs, Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor, J. Clin. Invest. 70 (1982) 965-977.
126. T. Sano, S.L. Asa, K. Kovacs, Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations, Endocr. Rev. 9 (1988) 357-373.